Trial · NCT03406338
Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease
NCT03406338, Phase 4, Active not recruiting, Region Skane
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease. Trials, record NCT03406338. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03406338
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease
- NCT number
- NCT03406338
- Status
- Active not recruiting
- Phases
- Phase 4
- Enrollment
- 60 participants, actual
- Lead sponsor
- Region Skane
- Conditions
- Dupuytren Disease of Finger
- Interventions
- Fasciectomy, Collagenase Clostridium Histolyticum
- First posted
- 2018-01-23
- Last updated
- 2025-04-16
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total active extension deficit (metacarpophalangeal plus proximal interphalangeal joints) | Change from baseline to 3 months | Extension deficit of the metacarpophalangeal and interphalangeal joints of the treated finger measured with hand-held goniometer (0 degrees indicates no extension deficit) |
| Primary | Proportion of patients with worsening in total active extension deficit ≥20 degrees | 24 months compared to 3 months | Extension deficit of the metacarpophalangeal and interphalangeal joints of the treated finger measured with hand-held goniometer (0 degrees indicates no extension deficit) |
| Secondary | 11-item disabilities of the arm, shoulder and hand (QuickDASH) score | Change over time from from baseline, 3 weeks, 6 weeks, 3 months, 12 months, 24 months and 60 months | A patient-reported outcome measure of activity limitations related to upper extremity disorders, with total score range from 0 (best) to 100 (worst) |
| Secondary | EuroQoL 5-dimensions (EQ-5D) Index | Change over time from from baseline, 3 weeks, 6 weeks, 3 months, 12 months, 24 months and 60 months | Health-status and quality-of-life patient-reported measure, consists of 5 items, a single weighted score, the EQ-5D index, is calculated from the 5 dimensions, ranging from -0.594 (worst) to 1.0 (perfect health) |
| Secondary | Pain score | Change over time from from baseline, 3 weeks, 6 weeks, 3 months, 12 months, 24 months and 60 months | Visual analog scale of pain in the treated hand, score range from 0 (best) to 100 (worst) |
| Secondary | Satisfaction score | 3 weeks, 6 weeks, 3 months, 12 months, 24 months and 60 months | Visual analog scale of patient satisfaction with treatment outcome, score range from 0 (best) to 100 (worst) |
| Secondary | Adverse events | Anytime during 24 months after treatment | All observed and reported adverse events will be recorded on a standard form. Serious adverse events include nerve, artery or tendon damage, deep infection, complex regional pain syndrome and any complications requiring surgery or hospital admission. |
| Secondary | Costs | From baseline through 24 months | Total treatment cost, direct (medications, surgery, materials, visits etc) and indirect (sick leave related to the treatment) |
| Secondary | Total active motion | Change from baseline to 3 months, 12 months, 24 months and 60 months | Sum of active range of motion of metacarpophalangeal, proximal intephalangeal and distal interphalangeal joints of the treated finger |
| Secondary | Total active extension deficit (metacarpophalangeal plus proximal interphalangeal joints) | Change from baseline to 12 months, 24 months and 60 months | Active extension deficit of the metacarpophalangeal and interphalangeal joints of the treated finger measured with hand-held goniometer (0 degrees indicates no extension deficit) |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30808670 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03406338
GET https://conductscience.org/api/trials/v1/NCT03406338/registered